Viridian Therapeutics, Inc.\DE (VRDN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 25M 50M 75M FY13: 5.5M FY14: 6.5M FY15: 5.7M FY16: 3.5M FY17: 4M FY18: 8.4M FY19: 4.5M FY20: 1.1M FY21: 3M FY22: 1.8M FY23: 314K FY24: 302K FY25: 70.8M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 1.5M 3M 4.5M FY13: 2.7M FY14: 3.1M FY15: 3.2M FY16: 929K FY13 FY14 FY15 FY16

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-450M -300M -150M 0 150M 300M 450M FY13: -197K FY14: -6.9M FY15: -11.2M FY16: -17M FY17: -26.5M FY18: -33.1M FY19: -42M FY20: -110.4M FY21: -79.7M FY22: -134.3M FY23: -254.4M FY24: -299M FY25: -363.4M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-450M -300M -150M 0 150M 300M 450M FY13: -2.2M FY14: -7.9M FY15: -11.3M FY16: -17.3M FY17: -26.5M FY18: -32.7M FY19: -41.9M FY20: -110.7M FY21: -79.4M FY22: -129.9M FY23: -237.7M FY24: -269.9M FY25: -342.6M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 1.5M 3M 4.5M FY13: 2.8M FY14: 3.4M FY15: 2.5M FY16: 2.5M FY13 FY14 FY15 FY16

Operating Cash Flow Annual

-300M -200M -100M 0 100M 200M 300M FY13: -1.2M FY14: -2.2M FY15: -6.9M FY16: -14.8M FY17: -28.2M FY18: -26.8M FY19: -36.1M FY20: -29.8M FY21: -54.6M FY22: -93.8M FY23: -184.2M FY24: -232.3M FY25: -276.4M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-300M -200M -100M 0 100M 200M 300M FY13: -1.2M FY14: -2.5M FY15: -7M FY16: -15M FY17: -28.4M FY18: -27.3M FY19: -36.1M FY20: -29.8M FY21: -54.9M FY22: -94.6M FY23: -185.1M FY24: -232.8M FY25: -276.9M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 20M 40M 60M FY20: 3.6M FY21: 11.9M FY22: 32.1M FY23: 44.8M FY20 FY21 FY22 FY23

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q1 '14: -5.37 Q2 '14: -9.86 Q3 '14: -9.91 Q4 '14: -3.50 Q1 '15: -0.42 Q2 '15: 3.98 Q3 '15: 3.99 Q4 '15: -21.04 Q1 '16: -26.17 Q2 '16: -31.72 Q3 '16: -38.25 Q4 '16: -27.58 Q1 '17: -22.60 Q2 '17: -17.06 Q3 '17: -10.41 Q4 '17: -1.50 Q1 '18: -1.08 Q2 '18: -1.03 Q3 '18: -1.05 Q4 '18: -1.09 Q1 '19: -1.29 Q2 '19: -1.29 Q3 '19: -1.36 Q4 '19: -1.34 Q1 '20: -3.61 Q2 '20: -5.14 Q3 '20: -6.26 Q4 '20: -31.26 Q1 '21: -31.52 Q2 '21: -31.91 Q3 '21: -31.68 Q4 '21: -7.08 Q1 '22: -5.15 Q2 '22: -4.00 Q3 '22: -3.61 Q4 '22: -4.07 Q1 '23: -4.70 Q2 '23: -4.91 Q3 '23: -5.14 Q4 '23: -5.31 Q1 '24: -4.49 Q2 '24: -4.24 Q3 '24: -4.30 Q1 '14 Q3 '15 Q1 '17 Q3 '18 Q1 '20 Q3 '21 Q1 '23 Q3 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.